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Background. The manifestations of non-alcoholic fatty liver disease in patients who have undergone
pancreatoduodenectomy differ from those associated with obesity-related non-alcoholic fatty liver disease.
This study aimed to identify factors that predicted the occurrence of and recovery from non-alcoholic fatty
liver disease after pancreatoduodenectomy.
Methods. This retrospective study included 120 patients who underwent pancreatoduodenectomy
between April 2004 and December 2013. Non-alcoholic fatty liver disease was diagnosed using
unenhanced computed tomography as a value of <40 Hounsfield units. Recovery from non-alcoholic
fatty liver disease was based on increases in liver computed tomographic attenuation values. Pre-, intra-,
and postoperative factors were analyzed using univariate analysis and multivariable logistic regression
models.
Results. Non-alcoholic fatty liver disease occurred after pancreatoduodenectomy in 45 patients (38%),
and in 11 of 41 patients (27%) who received prophylactic pancreatic enzyme supplementation therapy
and in 34 of 79 patients (43%) who did not (P = .082). Six patients received therapeutic supple-
mentation after diagnosis. The non-alcoholic fatty liver disease recovery rates in patients who did and
did not receive pancreatic enzyme supplementation therapy were 100% and 58%, respectively
(P = .069). Multivariable analysis identified a high body mass index, small pancreatic volume, long
operative time, and a high aspartate aminotransferase/alanine aminotransferase ratio 1 month after
pancreatoduodenectomy as independent risk factors. A small diameter main pancreatic duct, a low
serum amylase level at postoperative day 28, and a high minimum liver computed tomographic value
predicted recovery from non-alcoholic fatty liver disease.
Conclusion. The non-alcoholic fatty liver disease occurrence rate in patients undergoing pancreato-
duodenectomy is high, but in about half of these patients, non-alcoholic fatty liver disease will resolve
without any enzyme supplementation. Prophylactic supplementation in the postoperative management of
pancreatoduodenectomy patients should be based on risk factors, and therapeutic supplementation
should be based on recovery factors. (Surgery 2016;160:318-30.)From the Department of Gastroenterological Surgery, Nagoya City University Graduate School of Medical
Sciences, Nagoya, JapanPANCREATODUODENECTOMY (PD) IS ONE OF THE MOST
INVASIVE OPERATIONS in gastroenterologic surgery.
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URGERYterm survivors after PD has increased.1-3 There-
fore, the mechanisms involved in the development
of non-alcoholic fatty liver disease (NAFLD) after
PD and the appropriate treatment for NAFLD
have been receiving attention.4-10
In contrast to the postoperative changes in
patients who have undergone PD, the postoperative
metabolic changes in patients who have undergone
total pancreatectomy are well known. Often,
pancreatectomy results inmanifestations associated
with nutritional disturbances, including weight
loss, hypoalbuminemia, diabetes mellitus, steator-
rhea, lipid malabsorption, lipid-soluble vitamin
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Although most human organs have functional re-
serves, loss of exocrine function in the pancreas is
clearly proportional to how much of the organ
has been resected. A previous study found that
malnutrition occurs in patients who have under-
gone resection of 90% of the pancreas.14 Further-
more, the frequency of NAFLD is greater after PD
than after distal pancreatectomy,8 but few studies
have investigated the effects of PD on pancreatic
exocrine function.
NAFLD has become widespread and is associ-
ated with the increasing prevalence of obesity.15-18
NAFLD after PD, however, has manifestations that
differ from NAFLD associated with obesity.5,7
Though only a few reports have been published,4,5
previous investigations of NAFLD after PD have
identified some of the risk factors associated with
its development and have determined that pancre-
atic enzyme replacement therapy provides some
benefits. Furthermore, the risk factors are varied,
and the effects of the reconstruction methods
used were not examined.5,7,9,10 Moreover, the effi-
cacy of pancreatic enzyme replacement therapy in
the prevention of and recovery from NAFLD has
not been clarified. This retrospective study had 2
aims, namely, to evaluate previously reported and
other potential risk factors for NAFLD after PD
and to assess the factors that affect recovery from
NAFLD after PD.
METHODS
Patients. Our study included 127 consecutive
patients who had undergone conventional PD or
pylorus-preserving PD, subtotal stomach-preserving
PD that involves dividing the stomach 2–3 cm
proximal to the pylorus ring and resecting all of
the duodenum, gallbladder, common bile duct,
and the head of the pancreas,19 at Nagoya City Uni-
versity Hospital between April 2004 and December
2013. Until March 2007, the reconstruction proce-
dure was based on the Imanaga method,20 which
involves external drainage of the main pancreatic
duct (MPD). In April 2007, the reconstruction pro-
cedure was changed to a modified Child method,21
which involves an end-to-side pancreaticojejunos-
tomy plus a Braun anastomosis, with external
drainage of the MPD. We excluded 4 patients
who changed hospitals during the early postopera-
tive period and who never underwent postoperative
computed tomography (CT) at our institute, 2 pa-
tients who underwent total remnant pancreatec-
tomy within 3 months after PD, and 1 patient
who had NAFLD preoperatively, leaving a total of
120 patients who were analyzed. Postoperativepancreatic enzyme supplements were not adminis-
tered routinely, except to patients with diarrhea.
When pancreatic enzyme supplementation therapy
was administered, the start and end dates of its
administration were recorded. Changes of
the brand of drug and quantity in the panc-
reatic enzyme drug administered were also
noted. Supplementation therapy was prescribed
to treat postoperative diarrhea or at each surgeon’s
discretion, but we were unable to use the medical
records to differentiate diarrhea from steatorrhea.
When pancreatic enzyme supplementation therapy
was started during the early postoperative period
and before NAFLD was diagnosed, we considered
that it was administered prophylactically for
NAFLD after PD, even if the supplement was
administered to treat diarrhea. When pancreatic
enzyme supplementation began after NAFLD was
diagnosed, it was considered to be a therapeutic
administration. If a patient was already receiving
prophylactic supplementation, a change in the
drug administered or an increase in dosage was
considered to be therapeutic supplementation.
The administration of perioperative radiation
and/or chemotherapy was recorded and included
notes on their regimens and durations. The volume
of pancreatic juice output through the external
MPD stent was measured every day until stent
removal. We reviewed the clinical records and all
of the CT images for each patient retrospectively.
Diagnosis of the occurrence of and recovery
from NAFLD after PD. All patients underwent
preoperative and postoperative abdominal CTs.
Preoperative dynamic CTs were performed and
were saved as thin-slice (1–3 mm) images. The
post-PD CTs were performed within 3 months on
85.0% (102/120) of the patients, within 6 months
on 95.8% (115/120) of the patients, and within
1 year on 100% of the patients (120/120). Routine
follow-up intervals for CTwere once every 6 months
or once per year. We reviewed all preoperative CTs
and as many of the postoperative follow-up CTs as
possible. The CT images obtained during the
terminal stages of malignant disease were excluded
from the assessments of NAFLD after PD. The CT
attenuation of the liver was measured at 3 locations
on unenhanced images. We calculated the mean
CT attenuation value for the liver and defined a
hepatic CT value of <40 Hounsfield units (HU) as
NAFLD.22 An increase of the hepatic CT attenua-
tion value was considered to be a “recovery.”
Normalization of the liver CT attenuation value
by $40 HU was considered to be a “full recovery,”
and an increase of the liver CTattenuation value of
<40 HU was considered a “partial recovery.”
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volumetry. Using the thin-slice CT images ob-
tained preoperatively, the preoperative pancreatic
volume was measured with a volume analyzer
(Synapse Vincent; Fujifilm Medical Co, Ltd, Tokyo,
Japan). Detectable tumors, cysts, the MPD, and the
common bile duct were eliminated from the
pancreatic volume in the 3-dimensional images.
The volume of the remnant pancreas was calcu-
lated based on the pancreas’ dividing line
(supplementary Fig 1, online version only).
Remnant pancreatic rate was calculated as [Vol-
ume of remnant pancreas]/[Total volume of the
pancreas]. The pancreatic thickness and the diam-
eter of the MPD were measured in all pre- and
postoperative CT images. The pancreatic thickness
was measured at the midpoint of the remnant
pancreas after PD. The pancreas’ dividing line
was confirmed during the reviews of the surgical
records. The thickness of the pancreatic paren-
chyma was calculated as the “pancreatic thickness”
minus the “diameter of the MPD.” A change in the
thickness of the pancreatic parenchyma was as-
sessed using ratios derived from the pre- and post-
operative values.
Evaluation of factors affecting the risk of and
recovery from NAFLD after PD. We evaluated the
pre-, intra-, and postoperative factors that might be
associatedwith thedevelopment of or recovery from
NAFLD after PD. The preoperative factors included
age, sex, body mass index (BMI), preoperative
jaundice, diabetes mellitus, hyperlipidemia,
chronic pancreatitis, the diagnosis, the mean he-
patic CT attenuation value, the pancreatic volume,
the diameter of the MPD, the thickness of the
pancreatic parenchyma, and laboratory parameters
that included the hemoglobin, platelet count,
serum levels of glycated hemoglobin, total protein,
albumin, total cholesterol, triglyceride, C-reactive
protein, amylase, aspartate aminotransferase
(AST), alanine aminotransferase (ALT), carci-
noembryonic antigen, and carbohydrate antigen
19-9 levels. The intraoperative factors included the
resection and reconstruction methods, resection of
the nerve plexus around the superior mesenteric
artery, the operative time, and the volume of blood
lost. The postoperative factors included the volume
of the pancreatic juice output, complications based
on the Clavien-Dindo classification,23 the presence
of pancreatic fistulae based on the International
Study Group on Pancreatic Fistula criteria,24 the
duration of the presence of theMPD stent, the pres-
ence of postoperative diarrhea and timing, the use
of anti-diarrheal therapy, changes in body weight
at 2 and 4 weeks postoperatively, the laboratoryparameters, and all of the CT parameters, which
were assessed until the patient died or until the
end of the follow-up period at our institution.
Risk scoring system for NAFLD after PD. Based
on the results of a multivariable analysis of the risk
factors for NAFLD, we developed a risk scoring
system to estimate the possibility of developing
NAFLD after PD. Each score was determined based
on the odds ratios (ORs) of the independent risk
factors. The cut-off points were chosen based on
the occurrence rates of NAFLD in all patients. The
patients were categorized into “low-risk” and “high-
risk” groups. The occurrence of NAFLD was
compared using a log-rank test. The 90% confi-
dence intervals (CIs) of the ORs were calculated
using the bootstrap method.
Statistical analyses. Student t test or Welch t test
was used to analyze the continuous variables based
on the results from the F-test. The v2 test or Fisher
exact test was used to analyze the categorical vari-
ables based on a minimum expectation of <5. All
of the continuous variables’ cut-off points were
determined using receiver operating characteristic
(ROC) curves. Univariate and multivariable logis-
tic regression analyses were used to identify the
risk factors associated with the development of
NAFLD after PD. All of the factors that were statis-
tically significant in the univariate analysis were
subjected to multivariable logistic regression anal-
ysis. The factors that were associated with recovery
from NAFLD were also analyzed using univariate
and multivariable logistic regression analyses. Sur-
vival and occurrence analyses were conducted us-
ing the Kaplan-Meier method, and the results
were compared using the log-rank test. All of the
statistical analyses were performed using IBM
SPSS Statistics for Windows, version 23.0 (IBM Cor-
poration, Armonk, NY).
RESULTS
Patient characteristics. The mean age was
67.6 years, and the male-to-female ratio was
82:38. The indications for PD included pancreatic
ductal adenocarcinoma (n = 43, 35.8%), ampullary
carcinoma (n = 23, 19.2%), intraductal papillary
mucinous neoplasm (n = 19, 15.8%), bile duct
carcinoma (n = 13, 10.8%), ampullary adenoma
(n = 3, 2.5%), chronic pancreatitis (n = 3, 2.5%),
duodenal carcinoma (n = 3, 2.5%), autoimmune
pancreatitis (n = 2, 1.7%), and others (n = 11,
9.2%). Conventional PD was performed in 19 pa-
tients, pylorus-preserving PD in 26, and subtotal
stomach-preserving PD in 75, with an Imanaga
reconstruction in 27, and a modified Child recon-
struction in 93. Six (5%) patients received
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Fig 1. Kaplan-Meier estimates of the incidence of NAFLD
after PD according to sex. NAFLD, Non-alcoholic fatty
liver disease; PD, pancreatoduodenectomy.
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Fig 2. Kaplan-Meier estimates of overall survival in pa-
tients who developed NAFLD after PD and those who
did not. NAFLD, Non-alcoholic fatty liver disease; PD,
pancreatoduodenectomy.
Surgery
Volume 160, Number 2
Sato et al 321postoperative radiation therapy, and 23 (19.2%)
received adjuvant chemotherapy, comprising S-1
in 10, gemcitabine in 9, tegafur/uracil in 3, and
imatinib in 1. The mean duration of the observa-
tion period was 34.6 months (median 27.8, range
1.3–118.0 months).
Occurrence rate of NAFLD. De novo NAFLD
was diagnosed in 45 of 120 (37.5%) patients.
Prophylactic pancreatic enzyme supplementation
therapy was prescribed to 41 out of 120 (34.2%)
patients, and NAFLD was diagnosed in 11 out of 41
(27%) of these patients. NAFLD was diagnosed in
34 of the 79 (43%) patients who did not receive
prophylactic pancreatic enzyme supplementation
therapy (P = .082).
Time until diagnosis of NAFLD after PD. The
mean time to a diagnosis of NAFLD was
9.1 ± 10.7 months after PD (median 5.5, range
0.36–57.1 months), and 77.8% of the patients were
diagnosed with NAFLD within 12 months of the
operation. The female patients were diagnosed
with NAFLD earlier (156 ± 109 days) than the male
patients (380 ± 407 days, P = .018). The Kaplan-
Meier curves are shown in Fig 1. One patient did
not develop NAFLD until 57.1 months after opera-
tion. Although according to CT images, this pa-
tient had not developed NAFLD at 51.9 months
postoperatively and had received pancreatic
enzyme supplementation therapy until 52 months
postoperatively, NAFLD occurred after supplemen-
tation ceased.
Outcomes of patients with NAFLD after PD. Of
the 45 patients diagnosed with NAFLD, 6 received
therapeutic pancreatic enzyme supplementation
after diagnosis. All of these patients showed someextent of recovery (100%), and 4 patients had full
recoveries. The therapeutic drug administered was
delayed-release pancrelipase (LipaCreon; Eisai Co,
Ltd, Tokyo, Japan). Full-dose pancreatic enzyme
supplementation therapy (1,800 mg/day) was pre-
scribed to 4 patients, all of whom showed full
recoveries. The other 2 patients, who were admin-
istered half-dose pancreatic enzyme supplementa-
tion therapy, showed partial recoveries. Of the 39
patients who did not receive therapeutic pancreatic
enzyme supplementation, 21 showed recoveries
(54%) and 20 showed full recoveries (51%). Among
the patients who recovered from NAFLD spontane-
ously, 55% recovered within 6 months, and 90%
recovered within 1 year. The recovery rate tended to
be greater in patients who had received therapeutic
pancreatic enzyme supplementation (100% vs 54%,
P = .069). Two NAFLD patients who did not receive
pancreatic enzyme supplementation therapy died
of liver failure. The Kaplan-Meier curves are shown
in Fig 2. The occurrence of NAFLD did not affect
prognosis (P = .716).
Perioperative characteristics of the patients who
developed NAFLD after PD. Table I shows the
pre-, intra-, and postoperative characteristics of
the patients in relation to the development of
NAFLD after PD. More detailed data are presented
in supplementary Table I (online version only). In
relation to the preoperative factors, the group who
developed NAFLD after PD had greater BMI
(P = .013). The proportion of females was greater
in the group who developed NAFLD after PD
(47% vs 23%, P = .006), and the group who devel-
oped NAFLD after PD had a greater prevalence of
hyperlipidemia after PD (20% vs 5%, P = .017).
Table I. Factors in relation to NAFLD after PD
Variables (mean ± SD or n)
With NAFLD
n = 45
Without NAFLD
n = 75 P value
Preoperative factors
Body mass index (kg/m2) 22.5 ± 3.2 21.2 ± 2.5 .013*
Sex (male/female), n 24/21 58/17 .006y
Hyperlipidemia (+/), n 9/36 4/71 .017*
Diabetes mellitus (+/), n 13/32 11/64 .059
CT value of the liver (HU) 58.3 ± 6.9 58.9 ± 7.0 .638
Platelet counts (3103/mL) 204.2 ± 59.6 227.8 ± 61.2 .042*
Hemoglobin A1c (%) 6.8 ± 2.1 6.0 ± 1.3 .039*
Serum amylase (IU/L) 87.8 ± 52.1 120.9 ± 112.2 .065
Diameter of MPD (mm) 2.7 ± 1.9 2.4 ± 1.9 .355
Pancreatic parenchyma (mm) 15.6 ± 3.9 17.3 ± 4.7 .053
Total volume of the pancreas (mL) 51.7 ± 23.5 63.6 ± 25.5 .013*
Operative factors
Operation time (min) 565.2 ± 158.9 501.2 ± 152.8 .031*
Blood Loss (mL) 1,677 ± 1,463 1,528 ± 1,559 .606
Resection (PD/PpPD/SSPPD), n 9/6/30 10/20/45 .192
Nerve plexus resection (+/), n 16/29 16/59 .069
Reconstruction (Imanaga/Child), n 7/38 20/55 .158
Volume of remnant pancreas (mL) 24.4 ± 13.3 32.8 ± 15.2 .003y
Remnant pancreatic rate (%) 46.6 ± 9.7 50.7 ± 9.6 .031*
Postoperative factors
MPD stent removal (POD) 27.1 ± 12.2 27.2 ± 9.6 .989
Pancreatic juice output (mL/day)
POD 7 80.7 ± 71.4 134.8 ± 102.7 .004y
POD 14 91.1 ± 76.2 145.6 ± 114.4 .010y
POD 21 101.8 ± 80.0 137.9 ± 116.2 .157
Serum amylase (IU/L)
POD 7 56.4 ± 55.1 57.5 ± 51.2 .909
POD 14 42.1 ± 28.2 55.7 ± 34.9 .028*
POD 28 51.4 ± 34.3 63.6 ± 47.9 .140
Blood examination at 1 mo after operation
Platelet count (3103/mL) 220.5 ± 67.5 248.6 ± 90.5 .073
AST (IU/L) 36.8 ± 19.0 38.9 ± 25.5 .619
ALT (IU/L) 44.7 ± 27.6 57.4 ± 44.3 .055
AST/ALT ratio 0.94 ± 0.40 1.06 ± 0.47 .174
*P < .05.
yP < .01.
ALT, Alanine aminotransferase; AST, aspartate aminotransferase; CT, computed tomography; HU, Hounsfield unit; MPD, main pancreatic duct; NAFLD,
non-alcoholic fatty liver disease; PD, pancreatoduodenectomy; POD, postoperative day; PpPD, pylorus-preserving pancreatoduodenectomy; SD, standard
deviation; SSpPD, subtotal stomach-preserving pancreatoduodenectomy.
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lower platelet counts, greater glycated hemoglobin
levels, and smaller preoperative pancreatic vol-
umes (P # .05 each). In relation to the intraoper-
ative factors, the operative time was greater; the
remnant pancreas was smaller in volume; and the
remnant pancreatic rate (remnant pancreatic
rate = [volume of the remnant pancreas] / [preop-
erative total volume of the pancreas]) was less in
the group who developed NAFLD (P # .04 each).
In relation to the resection and reconstruction
methods, the differences between the patients
who developed NAFLD after PD and those whodid not were insignificant. In relation to the post-
operative factors, the outputs of pancreatic juice
volumes on postoperative days (PODs) 7 and 14
were less in the patients who developed NAFLD.
Regarding the laboratory assessments performed
within 1 month after PD, only the serum amylase
level on POD 14 was less in the patients who devel-
oped NAFLD. The postoperative serum amylase
level was generally less in the patients who devel-
oped NAFLD.
Influence of NAFLD on the nutritional status
and pancreatic CT images. Table II compares
the periods “during NAFLD” and “during
Table II. Comparison of clinical data between the period of NAFLD and non-NAFLD
Variables (mean ± SD or n)
During non-NAFLD
n = 497
During NAFLD
n = 149 P value
Findings of CT images
CT value of the liver (HU) 57.0 ± 7.4 21.6 ± 14.8 <.001y
CT value of the spleen (HU) 48.6 ± 3.7 48.7 ± 3.7 .907
Liver/spleen ratio 1.25 ± 1.81 0.46 ± 0.31 <.001y
Diameter of the MPD (mm) 1.4 ± 1.1 1.5 ± 1.1 .404
Pancreatic parenchyma (mm) 13.4 ± 4.4 10.6 ± 3.7 <.001y
Change of pancreatic parenchyma (%) 97.7 ± 37.5 91.6 ± 37.2 .086
Findings of laboratory examinations
Total protein (g/dL) 6.8 ± 0.7 6.6 ± 0.7 .003y
Albumin (g/dL) 3.8 ± 0.6 3.6 ± 0.7 .001y
Total cholesterol (mg/dL) 151.8 ± 40.6 120.7 ± 31.2 <.001y
Triglyceride (mg/dL) 106.5 ± 51.5 91.8 ± 34.8 <.001y
C-reactive protein (mg/dL) 1.3 ± 2.9 0.9 ± 2.5 .145
Serum amylase (IU/L) 81.0 ± 118.1 65.3 ± 64.3 .042*
AST (IU/L) 32.2 ± 21.5 50.6 ± 39.8 <.001y
ALT (IU/L) 30.1 ± 27.0 41.4 ± 24.6 <.001y
AST/ALT ratio 1.3 ± 0.5 1.3 ± 0.4 .600
*P < .05.
yP < .01.
ALT, Alanine aminotransferase; AST, aspartate aminotransferase; CT, computed tomography; HU, Hounsfield unit; MPD, main pancreatic duct; NAFLD,
non-alcoholic fatty liver disease; SD, standard deviation.
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ages and the evaluations at the same time points.
The liver CT value was less during NAFLD. The
pancreatic parenchyma was thinner during
NAFLD (P < .001). Although the differences
were small, the total protein, albumin, total choles-
terol, and triglyceride levels were significantly less
during NAFLD. The serum amylase level was less,
and the AST and ALT levels were greater during
NAFLD (P # .05).
Risk factors for the de novo development of
NAFLD after PD. Table III presents the analysis of
the risk factors for the development of NAFLD af-
ter PD (the details of which are provided in
supplementary Table II, online only version).
The univariate analysis identified the following
as preoperative risk factors for the development
of NAFLD after PD, where “high” and “low” are
relative to the cut-off points determined
from the ROC analyses: female sex (OR
2.99, P = .006), high BMI of $22.0 kg/m2 (OR
2.34, P = .027), history of hyperlipidemia
(OR 4.44, P = .012), increased glycated hemoglo-
bin level of $7.0% (OR 2.66, P = .046), low hemo-
globin level of <12.2 g/dL (OR 2.15, P = .045),
low platelet count of <260 3 103/mL (OR 4.53,
P = .006), low serum amylase level of <75 IU/L
(OR 2.30, P = .031), thinner pancreatic paren-
chyma of <13.8 mm (OR 2.17, P = .032), and
smaller preoperative pancreatic volume of<53.4 mL (OR 3.58, P = .001). The following
were identified as intra- and postoperative risk fac-
tors for the development of NAFLD after PD: long
operative time of $583 minutes (OR 2.87,
P = .007), smaller remnant pancreatic volume of
<23.5 mL (OR 4.49, P = .001), lower remnant
pancreatic rate of <52.1% (OR 2.06, P = .049),
low serum amylase level on POD 28 of
<44 IU/L (OR 2.22, P = .036), low output volume
of pancreatic juice on POD 7 of <70 mL (OR
3.31, P = .004), low volume of pancreatic juice
on POD 14 of <90 mL (OR 2.93, P = .011),
AST/ALT ratio at 1 month after PD of $0.86
(OR 2.24, P = .039), atrophy of the pancreatic pa-
renchyma of <89.1% (OR 2.63, P = .041), and the
absence of a pancreatic fistula (OR 3.22, P = .002).
Malignancy, radiation therapy, and adjuvant
chemotherapy did not show any significant differ-
ences between those who developed NAFLD after
PD and those who did not (P $ .05 each). We used
all of the factors that were significant in the uni-
variate analysis in the multivariable logistic regres-
sion analysis.
The multivariable logistic regression analysis
identified the following as independent risk factors
for the development of NAFLD after PD: high BMI
(OR 12.2, P = .008), small pancreatic volume (OR
9.85, P = .012), long operative time (OR 6.35,
P = .023), and high AST/ALT ratio (OR 10.1,
P = .008).
Table III. Results of univariate and multivariable analysis of risk factors for NAFLD after PD
Variables
Univariate analysis Multivariable analysis
ScoreOR 95% CI
P
value OR 95% CI
P
value
Preoperative factors
Sex Female 2.99 1.35 6.62 .006y
Body mass index (kg/m2) $22.0 2.34 1.10 5.00 .027* 12.2 1.94 77.0 .008 3
Hyperlipidemia + 4.44 1.28 15.4 .012*
Diabetes mellitus + 2.36 0.95 5.86 .059
Hemoglobin A1c (%) $7 2.66 1.00 7.04 .046*
Hemoglobin (g/dL) <12.2 2.15 1.01 4.58 .045*
Platelet count (3103) <260 4.53 1.45 14.2 .006y
Serum amylase (IU/L) <75 2.30 1.07 4.96 .031*
Diameter of the
MPD (mm)
$2.2 1.88 3.96 0.89 .071
Pancreatic
parenchyma (mm)
<13.8 2.17 1.02 4.61 .032*
Total pancreatic
volume (mL)
<53.4 3.58 1.64 7.80 .001y 9.85 1.66 58.6 .012 2
Operative factors
Operative time (min) $583 2.87 1.32 6.25 .007y 6.35 1.30 31.1 .023 1
Blood loss (g) $1405 2.09 0.98 4.46 .054
Remnant pancreatic
volume (mL)
<23.5 4.49 2.03 9.92 .000y
Remnant pancreatic
rate (%)
<52.1 2.06 0.95 4.44 .049*
Nerve plexus resection + 2.03 0.89 4.63 .069
Procedure
(PD/PpPD/SSpPD)
    .192
Reconstruction
(Child or
Imanaga)
Child 1.97 0.76 5.13 .158
Postoperative factors
MPD stent removal
(POD)
<25 1.90 0.90 4.02 .068
Pancreatic juice output
POD 7 (mL/day) <70 3.31 1.44 7.61 .004y
POD 14 (mL/day) <90 2.93 1.27 6.79 .011*
Serum amylase
POD 7 (IU/L) <42 1.17 0.56 2.46 .671
POD 14 (IU/L) <38 2.03 0.96 4.31 .063
POD 28 (IU/L) <44 2.22 1.05 4.72 .036*
Complications
($ grade 3z)
+ 1.13 0.37 3.41 .521
Pancreatic fistula
($ grade Ax)
 3.22 1.49 6.97 .002y
Pancreatic fistula
($ grade Bx)
 1.45 0.60 3.55 .275
Diarrhea + 2.45 0.79 7.60 .099
Radiation therapy + 3.27 0.90 11.9 .099
Adjuvant chemotherapy + 1.59 0.76 3.35 .220
Preventive
supplementation
 2.06 0.91 4.69 .082
Body weight loss (%)
2 wk after operation <4.9 1.44 0.62 3.36 .262
4 wk after operation <4.7 1.51 0.57 3.98 .279
(continued)
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Table III. (continued)
Variables
Univariate analysis Multivariable analysis
ScoreOR 95% CI
P
value OR 95% CI
P
value
Change of thickness
of the pancreatic
parenchyma (%)
<89.1 2.63 1.01 6.85 .041*
Blood examination
at 1 mo after
operation
Hemoglobin (g/dL) <10.5 1.50 0.69 3.26 .305
Platelet count (3103) <226 2.00 0.93 4.30 .074
Total protein (g/dl) $6.4 1.11 0.52 2.37 .796
Albumin (g/dl) <3.2 1.50 0.70 3.21 .295
AST (IU/L) $29 1.34 0.61 2.92 .462
ALT (IU/L) <45 1.31 0.62 2.80 .483
AST/ALT ratio $0.86 2.24 1.04 4.83 .039* 10.1 1.94 77.0 .008 2
Total cholesterol (mg/dl) <117 1.75 0.75 4.10 .193
Triglyceride (mg/dL) $104 1.27 0.53 3.03 .592
*P < .05.
yP < .01.
zClavien-Dindo classification.
xInternational Study Group of Pancreatic Fistula classification.
ALT, Alanine aminotransferase; AST, aspartate aminotransferase; MPD, main pancreatic duct; NAFLD, non-alcoholic fatty liver disease; PD, pancreatoduo-
denectomy; POD, postoperative day; PpPD, pylorus-preserving pancreatoduodenectomy; SD, standard deviation; SSpPD, subtotal stomach-preserving
pancreatoduodenectomy.
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for each independent risk factor based on the
results of the multivariable logistic regression
analysis. A long operative time, which had the least
OR of 6.4, was assigned 1 point. The factors that
had ORs that were close to 10, namely, small
pancreatic volume and high AST/ALT ratio, were
assigned 2 points, and high BMI, which had the
greatest OR of 12.2, was assigned 3 points
(Table III). Each score was applied to our data
retrospectively, and based on a total score of 8,
the cohort was divided into 2 groups, namely,
“low-risk” (total score #3) and “high-risk” (total
score $4) groups. The cut-off point was chosen
based on the NAFLD occurrence rate (n = 120,
37.5%), and the NAFLD occurrence rates were
20.6% (n = 63) in the low-risk group and 56.1%
(n = 57) in the high-risk group (P < .0001). The
OR was 5.6 (95% CI, 2.3–23.3). The Kaplan-
Meier curves are shown in Fig 3.
Factors associated with recovery from NAFLD
after PD. Table IV shows the results from the uni-
variate and multivariable logistic regression ana-
lyses of recovery from NAFLD after PD. The
cut-off points were chosen using an ROC curve
for a full recovery as the response variable. The
univariate analysis of the factors associated with re-
covery from NAFLD after PD showed that athinner preoperative MPD diameter, lower serum
amylase levels on PODs 14 and 28, a greater mini-
mum hepatic CT value, and a late diagnosis time
were significantly associated with recovery from
NAFLD after PD. The multivariable logistic regres-
sion analysis determined that a smaller diameter
preoperative MPD of <2.3 mm (OR 7.6,
P = .036), a greater minimum liver CT value of
$14.2 HU (OR 17.5, P = .023), and a lesser serum
amylase level on POD 28 of <43 IU/L (OR 18.3,
P = .023) were independently associated with re-
covery from NAFLD after PD. A lesser preoperative
hemoglobin level of <13.5 g/dL (OR 6.7, P = .033)
and a greater minimum hepatic CT value of $14.2
HU (OR 11.6, P = .033) were independently associ-
ated with a full recovery from NAFLD after PD.
DISCUSSION
The incidence of NAFLD after PD has been
reported to range from 7.8–40%,4-10,25,26 and such
a broad range could be associated with the
different durations of the observation periods,
which ranged from 3.2–21 months. In the current
study, NAFLD occurred in 37.5% of the patients
who underwent PD, which is within the range re-
ported in previous publications; however, the
time to the onset of NAFLD in some of our pa-
tients was greater than we anticipated. Indeed, 1
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Fig 3. Kaplan-Meier estimates of the incidence of
NAFLD after PD, based on whether the patients were
at high or low risk of developing NAFLD. ALT, Alanine
transaminase; AST, aspartate transaminase; BMI, body
mass index; NAFLD, non-alcoholic fatty liver disease;
PD, pancreatoduodenectomy.
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326 Sato et alpatient developed NAFLD 58 months after PD,
and 22% of the patients were diagnosed with
NAFLD more than 12 months after PD. These find-
ings suggest that prolonged follow up is required
for patients who have undergone PD.
NAFLD generally signifies overnutrition, but
NAFLD after PD has different clinical features.
Our data showed that the nutritional status of the
patients who developed NAFLD after PD was poor,
as determined by lower total protein, albumin,
total cholesterol, and triglyceride levels. Addition-
ally, the factors that are considered to reflect
pancreatic function---namely, the thickness of the
pancreatic parenchyma and the serum amylase
level---were also significantly less. These results
are consistent with data that suggest that the
main concern associated with the development of
NAFLD after PD is pancreatic dysfunction, which
affects patients’ digestion and absorption. Hence,
we wondered if pancreatic exocrine dysfunction
was the only risk factor associated with the devel-
opment of NAFLD after PD.
Many different types of risk factors associated
with the development of NAFLD after PD have
been reported,5-7,9,10,25,26 but the studies from
which these risk factors were reported had short
observation periods or small numbers of patients
with NAFLD, and few studies included multivari-
able regression analyses. Previous publicationsthat describe the development of NAFLD after
PD are summarized in Table V. Kato et al7 showed
that the presence of pancreatic adenocarcinoma,
the pancreatic resection line, and diarrhea were in-
dependent risk factors associated with the develop-
ment of NAFLD after PD, while Tanaka et al5
reported that cancer of the pancreatic head was
a significant risk factor associated with the devel-
opment of NAFLD after PD. Song et al10 reported
that the presence of a pancreatic fistula and an
external pancreatic duct stent were significant fac-
tors associated with the development of NAFLD af-
ter PD. Moreover, Sato et al9 reported that age
(younger), sex (female), small remnant pancreatic
volume, and infection on PODs 7–28 were signifi-
cant risk factors associated with the development
of NAFLD after PD. In our study, the multivariable
logistic regression analysis determined 4 indepen-
dent risk factors associated with the development
of NAFLD after PD. Although these factors have
not been described previously, some of the risks
determined by the present study’s univariate anal-
ysis to be associated with the development of
NAFLD after PD have been described previously.
A high BMI is generally considered a risk factor
for typical NAFLD, and we found that it was also
a risk factor for the development of NAFLD after
PD. Being female was a significant risk factor for
the development of NAFLD after PD in our univar-
iate analysis, and it was determined to be a risk fac-
tor in a previous study.9 The results from the
current study also showed that the female patients
developed NAFLD earlier than the male patients;
thus, female patients should be followed more
carefully than male patients. The preoperative
pancreatic volume was an independent risk factor
for the development of NAFLD after PD, and
other measured pancreatic values---namely, the
thickness of the pancreatic parenchyma, the
remnant pancreatic volume, the remnant pancre-
atic rate, and atrophy of the pancreatic paren-
chyma---were significant factors in the univariate
analysis. We consider that all these factors reflect
the poor nutritional condition of a patient post-
PD, because they will predict a low level of pancre-
atic exocrine function postoperatively. In our
institution, all patients undergo the placement of
an external pancreatic duct stent, and the output
volumes of the pancreatic juice are measured until
the stent is withdrawn. Although dependent on
the concentrations of the digestive enzymes, a
low volume of output should reflect a low level
of pancreatic exocrine function. Patients with
pancreatic fistulae should have some pancreatic
exocrine function, but pancreatic fistulae may
Table IV. Analysis of factors associated with recovery from NAFLD after PD
Variables
Univariate analysis Multivariable analysis
OR 95% CI
P
value OR 95% CI
P
value
Recovery
Preoperative diameter
of the MPD (mm)
<2.3 4.36 1.11 17.13 .030 7.6 1.1 50.9 .036
Serum amylase at
POD 14 (IU/L)
<44 3.67 0.99 13.62 .049
Serum amylase at
POD 28 (IU/L)
<43 3.74 1.00 13.92 .044 18.3 1.5 226.3 .023
Minimum liver CT
value (HU)
$14.2 3.74 1.00 13.92 .044 17.5 1.6 195.3 .020
NAFLD diagnosed
date (POD)
$112 4.40 1.1 17.5 .035
Full recovery
Preoperative diameter
of the MPD (mm)
<2.3 4.67 1.25 17.4 .019
Preoperative
BMI (kg/m2)
<23.0 4.22 1.11 16.0 .032
Preoperative
hemoglobin (g/dL)
<13.5 5.09 1.12 23.1 .031 6.7 1.2 38.7 .033
Minimum liver CT
value (HU)
$14.2 5.60 1.48 21.1 .010 5.9 1.2 28.6 .029
NAFLD diagnosed
date (POD)
$112 7.78 1.72 35.1 .006
Complications
(CD classification)
#2 2.71 1.79 4.12 .012
CI, Confidence interval; HU, Hounsfield unit; MPD, main pancreatic duct; NAFLD, non-alcoholic fatty liver disease; OR, odds ratio; PD, pancreatoduode-
nectomy; POD, postoperative day.
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function has been exhausted. The univariate anal-
ysis carried out in the present study showed that
the absence of pancreatic fistulae and lesser serum
amylase level were risk factors associated with
NAFLD development, which supports these
concepts.
It seems that pancreatic enzyme replacement
has become standard postoperative care for post-
PD patients in some institutions,4,5,8-10,27 but as far
as we are aware, these drugs have not been admin-
istered generally to pancreatectomized patients
until recently. Used as a prophylactic supplement
before the occurrence of diarrhea, pancreatic
enzyme replacement therapy was only routinely
administered to patients who had undergone total
pancreatectomy, but it was prescribed occasionally
at the surgeon’s discretion. These prescriptions
did not target NAFLD, and we defined all pancre-
atic enzyme supplementations as prevention or
therapy for NAFLD. In our study, only 34.2% of
the patients (41/120) were given pancreatic
enzyme replacement therapy that began shortly af-
ter PD and before NAFLD developed. The patientswho received pancreatic enzyme replacement ther-
apy had a lesser rate of NAFLD compared with
those who did not receive enzyme replacement
therapy (27% vs 43%, P = .082); therefore, we sug-
gest that prophylactic supplementation therapy
had a measurable effect. Nevertheless, we think
that pancreatic enzyme replacement therapy is
not always necessary for patients who undergo
PD, because the patients in our study who did
not receive therapeutic supplementation had a re-
covery rate of >50%. Furthermore, in most of the
recent studies, pancreatic enzyme supplementa-
tion therapy was administered to patients before
they developed NAFLD, and the NAFLD occur-
rence rates did not differ greatly from the rate in
the current study.
Some investigators have described the therapeu-
tic efficacy of pancreatic enzyme supplementation
for NAFLD. Tanaka et al5 prescribed another type
of pancreatic enzyme supplement to patients who
developed NAFLD after PD in addition to the sup-
plement that they were already receiving, and they
found that it significantly improved the liver/
spleen ratio, patient weight, the BMI, and the
Table V. Previous reports on the occurrence of NAFLD after PD
First
author Year
Incidence of
NAFLD (%, n)
Observation
period (mo)
Routine
supplementation Risk factor(s) by multivariable analysis
Nomura6 2007 33 (23/69) 12.1 (mean) Unknown —
Kato7 2010 37 (20/54) 7.7 (mean) + Pancreatic adenocarcinoma, pancreatic
resection line, postoperative diarrhea
Tanaka5 2011 23 (14/60) #12 + Pancreatic head cancer
Song10 2011 7.8 (15/193) 3.2 (mean) + Pancreatic fistula, external pancreatic
duct stent
Ito25 2014 12 (12/100) Unknown Unknown Blood loss
Sato9 2014 40 (44/110) #12 + Female, younger age, small remnant
pancreatic volume, suspicion of
infection
Kishi26 2015 17 (36/229) 21 (median)  —
Present
study
2016 37.5 (45/120) 34.6 (mean)  High body mass index, small pancreatic
volume, long operative time, high
AST/ALT ratio
ALT, Alanine aminotransferase; AST, aspartate aminotransferase; NAFLD, non-alcoholic fatty liver disease; PD, pancreatoduodenectomy.
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et al4 reported a prospective study in which the
administration of pancrelipase improved the
liver/spleen ratio in patients with NAFLD after
PD. Our data also showed the therapeutic benefit
of pancrelipase. The patients who received pancre-
lipase had better recovery rates than those who did
not receive therapy (100% vs 54%, P = .069), and
all of the patients who were prescribed full-dose
pancrelipase showed full recoveries. Given the re-
sults from previous studies and those from our
own study, we considered that it would be valuable
to identify the patients who actually require
pancreatic enzyme supplementation therapy. To
accomplish this, an analysis of recovery from
NAFLD was essential.
As far as we are aware, this is the first report to
describe the factors associated with recovery from
NAFLD after PD. Our study, however, was a
retrospective study that involved only 45 patients
who developed NAFLD after PD; hence, we could
detect only a few factors that were predictive of
recovery from NAFLD---namely, a thinner preop-
erative MPD, a lesser serum amylase level, and a
greater minimum hepatic CT value. Therefore,
based on our results, when patients develop
NAFLD after PD, we should pay particular atten-
tion to those who do not have these recovery
factors. We found that a low serum amylase level
was a common factor associated with the risk of
developing NAFLD after PD, and it affected recov-
ery time as well. A decrease in the exocrine
function of the pancreas is among the causes of
NAFLD after PD. We consider that if the main
cause of NAFLD after PD is a decrease in theexocrine function of the pancreas, patients could
easier develop NAFLD. Still, recovery will be easier
in patients with low serum amylase levels than in
those who have high serum amylase levels, because
the NAFLD in patients with high serum amylase
levels might not only be a consequence of
decreased pancreatic function; it could be associ-
ated with other factors, including chemotherapy,
radiation therapy, the patient’s general condition,
or other organ dysfunction. In this study, 2 patients
died from liver failure. These patients developed
NAFLD after PD, and pancreatic enzyme supple-
ments were not being administered. When our risk
scoring system was applied to these patients, both
belonged to the high-risk group. In relation to the
recovery factors, 1 patient had only 1 of the 3
factors associated with recovery, while the other
patient did not have any of the factors that are
associated with recovery. Hence, based on these
results and our experience of liver failure, we
recommend that if a patient has some risk factors
or is considered high risk, prophylactic pancreatic
enzyme supplementation therapy should be
administered, and our scoring system can assist
with such decision-making. If a patient develops
NAFLD and does not have any of the recovery
factors or has 1 factor only, therapeutic pancreatic
enzyme supplements should be administered.
When patients are receiving pancreatic enzyme
supplements, increasing the dose or changing the
drug should be effective. We consider that it is
difficult to assess pancreatic insufficiency from the
clinical symptoms or evaluations of the blood
alone, and findings from CT of the pancreas can
assist in its assessment. Although our study
Surgery
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NAFLD after PD and it has the greatest observation
period, the limitations of this study include its
retrospective design, the nonstandardized proto-
col for pancreatic enzyme supplementation, and
the small sample size. More large-scale studies
and/or prospective research are needed to clarify
these clinical questions and to derive robust
recommendations; studies may also evaluate the
use of pancreatic enzyme supplementation
routinely in all patients after PD.
In conclusion, surgeons should follow the post-
operative hepatic CT values of any patient who has
undergone PD even if the patient is receiving
pancreatic enzyme supplementation therapy, and
they should remember that NAFLD may develop
years after PD. The occurrence of NAFLD in
patients who have undergone PD requires long-
term follow up, even for those patients who are
receiving pancreatic enzyme supplementation
therapy; however, about half of the patients will
recover without the administration of any pancre-
atic enzyme drug. In the postoperative manage-
ment of patients who have undergone PD, the
administration of preventive supplementation
therapy should be based on risk factors, and
therapeutic supplementation should use the fac-
tors associated with recovery as reference points
for decision making. We should continue to study
the significance of therapeutic supplementation in
patients following PD.
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Supplementary data related to this article can be found
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